{"id":"W2084056567","doi":"10.1056/nejmoa0909169","title":"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":1735,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Royal Adelaide Hospital; Fondation pour la Recherche Médicale; Cambridge University Hospitals; National Institute for Health and Care Research; NIHR Cambridge Biomedical Research Centre; Kidney Foundation of Canada; Leids Universitair Medisch Centrum; Universiteit Leiden; University of Cambridge; Canadian Society of Nephrology; GlaxoSmithKline; Biogen; Wellcome Trust; F. Hoffmann-La Roche","keywords":"Medicine; Cyclophosphamide; Rituximab; Vasculitis; Anti-neutrophil cytoplasmic antibody; Adverse effect; Internal medicine; Refractory (planetary science); ANCA-Associated Vasculitis; Immunology; Gastroenterology; Antibody; Chemotherapy; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}